Research Article
Employing Adalimumab in Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Real-Life Multicenter Data from the Czech Republic
Table 2
Baseline clinical characteristics, adalimumab treatment and adverse events.
| | | N (percentage)/Mean (±SD) |
| | Baseline VAS | 5.2 (±2.7) | | Baseline DLQI | 17.6 (±7.3) | | Baseline white blood cell count × 109 | 10.6 (±2.9) | | Baseline CRP (mg/ml) | 20.3 (±22.3) | | Baseline IHS4 score | — | | Severe (≥11) | 249 (83.3%) | | Moderate (4–10) | 34 (11.4%) | | Mild (≤3) | 3 (1.0%) | | Biologic adalimumab treatment | 299 (100.0%) | | Humira | 287 (96.0%) | | Biosimilars (hulio, hyrimoz, idacio) | 12 (4.0%) | | Adalimumab treatment | 299 (100.0%) | | Length of adalimumab treatment (years) | 2.3 (±1.7) | | Discontinuation/termination of treatment | 66 (22.1%) | | Adverse events | 24 (8.0%) | | Infection | 14 (4.7%) | | Malignity | 3 (1.0%) | | Skin disorders | 4 (1.3%) | | Cholangitis | 1 (0.3%) | | Cerebrovascular disease | 1 (0.3%) | | Latent tuberculosis | 1 (0.3%) |
|
|
VAS, visual analogue scale; DLQI, dermatology life quality index; CRP, C-reactive protein; IHS4 score, the international hidradenitis suppurativa severity score system.
|
